Synthesis of Radiolabeled and Stable-Isotope Labeled Deucravacitinib (BMS-986165)

IF 0.9 4区医学 Q4 BIOCHEMICAL RESEARCH METHODS

Journal of labelled compounds & radiopharmaceuticals Pub Date : 2025-07-22 DOI:10.1002/jlcr.4156

John A. Brailsford, Kai Cao, Samuel J. Bonacorsi Jr.

引用次数: 0

Abstract

Deucravacitinib (BMS-986165) is a small molecule allosteric inhibitor of tyrosine kinase 2 (TYK2) currently approved for the treatment of moderate to severe plaque psoriasis. Tyrosine kinase 2 (TYK2) is a member of the Janus (JAK) family of non-receptor kinases that modulate the production of inflammatory cytokines. The synthesis of ¹⁴C-radiolabeled and stable-isotope labeled variants of deucravacitinib is described in this publication.

Abstract Image

查看原文本刊更多论文

放射性标记和稳定同位素标记Deucravacitinib （BMS-986165）的合成

Deucravacitinib （BMS-986165）是一种酪氨酸激酶2 （TYK2）的小分子变抑抑制剂，目前被批准用于治疗中度至重度斑块性银屑病。酪氨酸激酶2 （TYK2）是Janus （JAK）非受体激酶家族的一员，可调节炎症细胞因子的产生。本出版物描述了14c放射性标记和稳定同位素标记的deucravacitinib变体的合成。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of labelled compounds & radiopharmaceuticals 医学-分析化学

CiteScore

3.30

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： The Journal of Labelled Compounds and Radiopharmaceuticals publishes all aspects of research dealing with labeled compound preparation and applications of these compounds. This includes tracer methods used in medical, pharmacological, biological, biochemical and chemical research in vitro and in vivo. The Journal of Labelled Compounds and Radiopharmaceuticals devotes particular attention to biomedical research, diagnostic and therapeutic applications of radiopharmaceuticals, covering all stages of development from basic metabolic research and technological development to preclinical and clinical studies based on physically and chemically well characterized molecular structures, coordination compounds and nano-particles.